Maternal serum placental growth factor isoforms 1 and 2 at 11-13, 20-24 and 30-34 weeks' gestation in late-onset pre-eclampsia and small for gestational age neonates

Fetal Diagnosis and Therapy

Volumn 35, Issue 4, 2014, Pages 249-257

  Nucci, Marta ^a   Poon, Leona C ^a   Demirdjian, Gaiane ^b   Darbouret, Bruno ^b   Nicolaides, Kypros H ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Thermo Fisher Scientific   (United States)

Author keywords

Isoforms; Placental growth factor; Pre eclampsia; Pyramid; Small for gestational age

Indexed keywords

PLACENTAL GROWTH FACTOR; PLACENTAL GROWTH FACTOR 1; PLACENTAL GROWTH FACTOR 2; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; ISOPROTEIN; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR ISOFORM 1; PLACENTAL GROWTH FACTOR ISOFORM 2;

ARTICLE; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MATERNAL SERUM; NEWBORN; PREDICTION; PREECLAMPSIA; PREGNANCY OUTCOME; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY; SMALL FOR DATE INFANT; THIRD TRIMESTER PREGNANCY; BLOOD; CASE CONTROL STUDY; PREGNANCY; ADULT; COMPARATIVE STUDY; HOSPITAL BASED CASE CONTROL STUDY; MATERNAL AGE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, SMALL FOR GESTATIONAL AGE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; PROTEIN ISOFORMS;

EID: 84902553897     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000358595     Document Type: Article

References (20)

1. De Falco S: The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012; 44: 1-9
2. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683. (Pubitemid 38364626
3. Crispi F, Dominguez C, Llurba E, Martin-Gallan P, Cabero L, Gratacos E: Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006; 195: 201-207. (Pubitemid 43927524
4. Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH: Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008; 32: 732-739
5. Poon LC, Zaragoza E, Akolekar R, Anagnostopoulos E, Nicolaides KH: Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn 2008; 28: 1110-1115
6. Bersinger NA, Odegard RA: Second-And third-Trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand 2004; 83: 37-45. (Pubitemid 38121729
7. Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH: Maternal serum placental growth factor (PlGF) isoforms 1 and 2 at 11-13 weeks' gestation in normal and pathological pregnancies. Fetal Diagn Ther 2014, Epub ahead of print
8. Robinson HP, Fleming JE: A critical evaluation of sonar crown rump length measurements. Br J Obstet Gynaecol 1975; 182: 702-710
9. Nicolaides KH: Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011; 31: 7-15
10. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20:IX-XIV
11. Poon LC, Volpe N, Muto B, Syngelaki A, Nicolaides KH: Birthweight with gestation and maternal characteristics in live births and stillbirths. Fetal Diagn Ther 2012; 32: 156-165
12. Mathis G: Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin Chem 1993; 39: 1953-1959
13. Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ: Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998; 179: 1539-1544. (Pubitemid 29028397
14. Shore VH, Wang TH, Wang CL, Torry RJ, Caudle MR, Torry DS: Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997; 18: 657-665. (Pubitemid 27448423
15. Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH: Maternal serum placental growth factor, pregnancy-Associated plasma protein-A and free β-human chorionic gonadotrophin at 30-33 weeks in the prediction of pre-eclampsia. Fetal Diagn Ther 2013; 33: 164-172
16. Lai J, Larroca SG-T, Peeva G, Poon LC, Nicolaides KH: Maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks in the prediction of preeclampsia. Fetal Diagn Ther 2014, Epub ahead of print
17. Nicolaides KH: Turning the pyramid of prenatal care. Fetal Diagn Ther 2011; 29: 183-196
18. Lai J, Poon LCY, Pinas A, Bakalis S, Nicolaides KH: Uterine artery Doppler at 30-33 weeks' gestation in the prediction of preeclampsia. Fetal Diagn Ther 2013; 33: 156-163
19. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguere Y: Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-Analysis. Obstet Gynecol 2010; 116: 402-414
20. Roberge S, Villa P, Nicolaides KH, Giguere Y, Vainio M, Bakthi A, Ebrashy A, Bujold E: Early administration of low dose aspirin for the prevention of preterm and term pre-eclampsia: A systematic review and meta-Analysis. Fetal Diagn Ther 2012; 31: 141-146.